Fabry disease - current treatment and new drug development

Current Chemical Genomics

Volumn 4, Issue 1, 2010, Pages 50-56

  Motabar, Omid ^a   Sidransky, Ellen ^a   Goldin, Ehud ^a   Zheng, Wei ^a  

^a NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

Author keywords

Alpha galactosidase; Chaperone therapy; Drug development; Fabry disease; High throughput screening; Lysosomal storage disorders

Indexed keywords

1 DEOXYGALACTONOJIRIMYCIN; AGALSIDASE ALFA; AGALSIDASE BETA; AMIGAL; CARBAMAZEPINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GABAPENTIN; GLYCOSIDASE INHIBITOR; HISTAMINE H2 RECEPTOR ANTAGONIST; LOPERAMIDE; METOCLOPRAMIDE; MIGLUSTAT; NARCOTIC ANALGESIC AGENT; PANCRELIPASE; PHENYTOIN; UNCLASSIFIED DRUG;

ARTICLE; BLOOD BRAIN BARRIER; CLINICAL TRIAL; DRUG SCREENING; ENZYME ACTIVATION; ENZYME REPLACEMENT; FABRY DISEASE; GASTROINTESTINAL SYMPTOM; GENE THERAPY; HEMANGIOKERATOMA; HIGH THROUGHPUT SCREENING; HUMAN; IMMUNOFLUORESCENCE; KIDNEY FAILURE; NEUROPATHIC PAIN; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEINURIA; WESTERN BLOTTING;

EID: 78249238531     PISSN: None     EISSN: 18753973     Source Type: Journal    
DOI: 10.2174/1875397301004010050     Document Type: Article

References (62)

1. Desnick RJ, Ioannou YA, Eng CM. alpha-galactosidase A deficiency: Fabry disease. 8th ed. New York: McGraw-Hill Professional 2001; Vol. 1.
2. Meikle PJ, Hopwood JJ, Clague AE, Carey WF Prevalence of lysosomal storage disorders. JAMA 1999; 281: 249-54.
3. MacDermot KD, Holmes A, Miners AH. Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females. J Med Genet 2001; 38: 769-75.
4. Whybra C, Kampmann C, Willers I, et al. Anderson-fabry disease: clinical manifestations of disease in female heterozygotes. J Inherit Metab Dis 2001; 24: 715-24.
5. Ishii S, Chang HH, Kawasaki K, et al. Mutant alpha-galactosidase A enzymes identified in Fabry disease patients with residual enzyme activity: biochemical characterization and restoration of normal intracellular processing by 1-deoxygalactonojirimycin. Biochem J 2007; 406: 285-95.
6. Ishii S, Suzuki Y, Fan JQ. Role of Ser-65 in the activity of alphagalactosidase A: characterization of a point mutation (S65T) detected in a patient with Fabry disease. Arch Biochem Biophys 2000; 377: 228-33.
7. Ishii S, Kase R, Sakuraba H, Suzuki Y. Characterization of a mutant alpha-galactosidase gene product for the late-onset cardiac form of Fabry disease. Biochem Biophys Res Commun 1993; 197: 1585-9.
8. Brady RO. Enzyme replacement for lysosomal diseases. Annu Rev Med 2006; 57: 283-96.
9. Lidove O, Joly D, Barbey F, et al. Clinical results of enzyme replacement therapy in Fabry disease: a comprehensive review of literature. Int J Clin Pract 2007; 61: 293-302.
10. Eng CM, Guffon N, Wilcox WR, et al. Safety and efficacy of recombinant human alpha-galactosidase A--replacement therapy in Fabry's disease. N Engl J Med 2001; 345: 9-16.
11. Wilcox WR, Banikazemi M, Guffon N, et al. Long-term safety and efficacy of enzyme replacement therapy for Fabry disease. Am J Hum Genet 2004; 75: 65-74.
12. Moore DF, Scott LT, Gladwin MT, et al. Regional cerebral hyperperfusion and nitric oxide pathway dysregulation in Fabry disease: reversal by enzyme replacement therapy. Circulation 2001; 104: 1506-12.
13. Pierre-Louis B, Kumar A, Frishman WH. Fabry disease: cardiac manifestations and therapeutic options. Cardiol Rev 2009; 17: 31-5.
14. Lockman LA, Hunninghake DB, Krivit W, Desnick RJ. Relief of pain of Fabry's disease by diphenylhydantoin. Neurology 1973; 23: 871-5.
15. Lenoir G, Rivron M, Gubler MC, Dufier JL, Tome FS, Guivarch M. Fabry's disease. Carbamazepine therapy in acrodyniform syndrome. Arch Fr Pediatr 1977; 34: 704-16.
16. Germain DP. Fabry's disease (alpha-galactosidase-A deficiency): recent therapeutic innovations. J Soc Biol 2002; 196: 183-90.
17. Argoff CE, Barton NW, Brady RO, Ziessman HA. Gastrointestinal symptoms and delayed gastric emptying in Fabry's disease: response to metoclopramide. Nucl Med Commun 1998; 19: 887-91.
18. Mohrenschlager M, Braun-Falco M, Ring J, Abeck D. Fabry disease: recognition and management of cutaneous manifestations. Am J Clin Dermatol 2003; 4: 189-96.
19. Eng CM, Germain DP, Banikazemi M, et al. Fabry disease: guidelines for the evaluation and management of multi-organ system involvement. Genet Med 2006; 8: 539-48.
20. Remuzzi G, Schieppati A, Ruggenenti P. Clinical practice. Nephropathy in patients with type 2 diabetes. N Engl J Med 2002; 346: 1145-51.
21. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003; 348: 383-93.
22. Desnick RJ, Brady R, Barranger J, et al. Fabry disease, an underrecognized multisystemic disorder: expert recommendations for diagnosis, management, and enzyme replacement therapy. Ann Intern Med 2003; 138: 338-46.
23. Donati D, Sabbadini MG, Capsoni F, et al. Immune function and renal transplantation in Fabry's disease. Proc Eur Dial Transplant Assoc Eur Ren Assoc 1985; 21: 686-92.
24. Kramer W, Thormann J, Mueller K, Frenzel H. Progressive cardiac involvement by Fabry's disease despite successful renal allotransplantation. Int J Cardiol 1985; 7: 72-5.
25. Sands MS, Davidson BL. Gene therapy for lysosomal storage diseases. Mol Ther 2006; 13: 839-49.
26. Dwek RA, Butters TD, Platt FM, Zitzmann N. Targeting glycosylation as a therapeutic approach. Nat Rev Drug Discov 2002; 1: 65-75.
27. Cox T, Lachmann R, Hollak C, et al. Novel oral treatment of Gaucher's disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis. Lancet 2000; 355: 1481-5.
28. Elstein D, Hollak C, Aerts JM, et al. Sustained therapeutic effects of oral miglustat (Zavesca, N-butyldeoxynojirimycin, OGT 918) in type I Gaucher disease. J Inherit Metab Dis 2004; 27: 757-66.
29. Gelsthorpe ME, Baumann N, Millard E, et al. Niemann-Pick type C1 I1061T mutant encodes a functional protein that is selected for endoplasmic reticulum-associated degradation due to protein misfolding. J Biol Chem 2008; 283: 8229-36.
30. Balch WE, Morimoto RI, Dillin A, Kelly JW. Adapting proteostasis for disease intervention. Science 2008; 319: 916-9.
31. Powers ET, Morimoto RI, Dillin A, Kelly JW, Balch WE. Biological and chemical approaches to diseases of proteostasis deficiency. Annu Rev Biochem 2009; 78: 959-91.
32. Mu TW, Fowler DM, Kelly JW. Partial restoration of mutant enzyme homeostasis in three distinct lysosomal storage disease cell lines by altering calcium homeostasis. PLoS Biol 2008; 6: e26.
33. Bernier V, Lagace M, Bichet DG, Bouvier M. Pharmacological chaperones: potential treatment for conformational diseases. Trends Endocrinol Metab 2004; 15: 222-8.
34. Ulloa-Aguirre A, Janovick JA, Brothers SP, Conn PM. Pharmacologic rescue of conformationally-defective proteins: implications for the treatment of human disease. Traffic 2004; 5: 821-37.
35. Sawkar AR, Cheng WC, Beutler E, Wong CH, Balch WE, Kelly JW. Chemical chaperones increase the cellular activity of N370S beta -glucosidase: a therapeutic strategy for Gaucher disease. Proc Natl Acad Sci USA 2002; 99: 15428-33.
36. Sawkar AR, Adamski-Werner SL, et al. Gaucher diseaseassociated glucocerebrosidases show mutation-dependent chemical chaperoning profiles. Chem Biol 2005; 12: 1235-44.
37. Alfonso P, Pampin S, Estrada J, et al. Miglustat (NB-DNJ) works as a chaperone for mutated acid beta-glucosidase in cells transfected with several Gaucher disease mutations. Blood Cells Mol Dis 2005; 35: 268-76.
38. Zheng W, Padia J, Urban DJ, et al. Three classes of glucocerebrosidase inhibitors identified by quantitative high-throughput screening are chaperone leads for Gaucher disease. Proc Natl Acad Sci USA 2007; 104: 13192-7.
39. Okumiya T, Kroos MA, Vliet LV, Takeuchi H, Van der Ploeg AT, Reuser AJ. Chemical chaperones improve transport and enhance stability of mutant alpha-glucosidases in glycogen storage disease type II. Mol Genet Metab 2007; 90: 49-57.
40. Parenti G, Zuppaldi A, Gabriela Pittis M, et al. Pharmacological enhancement of mutated alpha-glucosidase activity in fibroblasts from patients with Pompe disease. Mol Ther 2007; 15: 508-14.
41. Tropak MB, Reid SP, Guiral M, Withers SG, Mahuran D. Pharmacological enhancement of beta-hexosaminidase activity in fibroblasts from adult Tay-Sachs and Sandhoff Patients. J Biol Chem 2004; 279: 13478-87.
42. Matsuda J, Suzuki O, Oshima A, et al. Chemical chaperone therapy for brain pathology in G(M1)-gangliosidosis. Proc Natl Acad Sci USA 2003; 100: 15912-7.
43. Shen JS, Edwards NJ, Hong YB, Murray GJ. Isofagomine increases lysosomal delivery of exogenous glucocerebrosidase. Biochem Biophys Res Commun 2008; 369: 1071-5.
44. Porto C, Cardone M, Fontana F, et al. The pharmacological chaperone N-butyldeoxynojirimycin enhances enzyme replacement therapy in Pompe disease fibroblasts. Mol Ther 2009; 17: 964-71.
45. Fan JQ, Ishii S. Active-site-specific chaperone therapy for Fabry disease. Yin and Yang of enzyme inhibitors. FEBS J 2007; 274: 4962-71.
46. Inglese J, Auld DS, Jadhav A, et al. Quantitative high-throughput screening: a titration-based approach that efficiently identifies biological activities in large chemical libraries. Proc Natl Acad Sci USA 2006; 103: 11473-78.
47. Mapes CA, Sweeley CC. Galactosyl (alpha 1-4)galactosylceramide: galactosyl hydrolase activity in normal and Fabry plasma. Biochem Biophys Res Commun 1973; 53: 1317-24.
48. Hultberg B, Sjoblad S, Ockerman PA. Glycosidases in human skin fibroblast cultures. Alpha-fucosidase, alpha-galactosidase, alphaglucosidase, beta-mannosidase, and N-acetyl-alphaglucosaminidase. Acta Paediatr Scand 1975; 64: 123-31.
49. Shi ZD, Motabar O, Goldin E, et al. Synthesis and characterization of a new fluorogenic substrate for alpha-galactosidase. Anal Bioanal Chem 2009; 394(7): 1903-9.
50. de Groot PG, Hamers MN, Westerveld A, et al. A new immunochemical method for the quantitative measurement of specific gene products in man-rodent somatic cell hybrids. Hum Genet 1978; 44: 295-304.
51. Yagi F, Eckhardt AE, Goldstein IJ. Glycosidases of Ehrlich ascites tumor cells and ascitic fluid-purification and substrate specificity of alpha-N-acetylgalactosaminidase and alpha-galactosidase: comparison with coffee bean alpha-galactosidase. Arch Biochem Biophys 1990; 280: 61-7.
52. Tsou KC, Su HC. A study of yeast alpha-galactosidase with naphthyl alpha-D-galactopyranosides as chromogenic substrates. Anal Biochem 1964; 8, 415-23.
53. Yam GH, Bosshard N, Zuber C, Steinmann B, Roth J. Pharmacological chaperone corrects lysosomal storage in Fabry disease caused by trafficking-incompetent variants. Am J Physiol Cell Physiol 2006; 290: C1076-82.
54. Yam GH, Zuber C, Roth J. A synthetic chaperone corrects the trafficking defect and disease phenotype in a protein misfolding disorder. FASEB J 2005; 19: 12-8.
55. Levery SB, Hakomori S. Microscale methylation analysis of glycolipids using capillary gas chromatography-chemical ionization mass fragmentography with selected ion monitoring. Methods Enzymol 1987; 138: 13-25.
56. Oshima M, Asano K, Shibata S, Suzuki Y, Masuzawa M. Urinary neutral glycosphingolipid analysis of patients with Fabry's disease; rapid isocratic elution from high-performance liquid chromatography as per-o-benzoyl derivatives. Biochim Biophys Acta 1990; 1043: 157-60.
57. Zeidner KM, Desnick RJ, Ioannou YA. Quantitative determination of globotriaosylceramide by immunodetection of glycolipid-bound recombinant verotoxin B subunit. Anal Biochem 1999; 267: 104-13.
58. Fauler G, Rechberger GN, Devrnja D, et al. Rapid determination of urinary globotriaosylceramide isoform profiles by electrospray ionization mass spectrometry using stearoyl-d35-globotriaosylceramide as internal standard. Rapid Commun Mass Spectrom 2005; 19: 1499-506.
59. Fan JQ, Ishii S, Asano N, Suzuki Y. Accelerated transport and maturation of lysosomal alpha-galactosidase A in Fabry lymphoblasts by an enzyme inhibitor. Nat Med 1999; 5: 112-5.
60. Shin SH, Murray GJ, Kluepfel-Stahl S, et al. Screening for pharmacological chaperones in Fabry disease. Biochem Biophys Res Commun 2007; 359: 168-73.
61. Ohshima T, Murray GJ, Swaim WD, et al. alpha-Galactosidase A deficient mice: a model of Fabry disease. Proc Natl Acad Sci USA 1997; 94: 2540-4.
62. Ishii S, Yoshioka H, Mannen K, Kulkarni AB, Fan JQ. Transgenic mouse expressing human mutant alpha-galactosidase A in an endogenous enzyme deficient background: a biochemical animal model for studying active-site specific chaperone therapy for Fabry disease. Biochim Biophys Acta 2004; 1690: 250-7